[
    "\n_MEF medium_\r\n\n\nDMEM \\(Life Technologies), 10% FBS \\(Hyclone), 1% nonessential amino acids \\(Life Technologies), 1mM GlutaMAX \\(Life Technologies), 1% Pen-strep \\(Life Technologies), 0.1mM beta-mercaptoethanol \\(Life Technologies) and 1mM sodium pyruvate \\(Life Technologies).\r\n\n\n\r\n\n\n_TeSR-E8 Medium_\r\n\n\nAdd 20ml of TeSR-E8 supplement \\(Stem Cell Technologies) to 500ml basal medium \\(Stem Cell Technologies), supplement with 1% Pen-strep \\(Life Technologies).\r\n\n\n\r\n\n\n_5i/LAF medium_\r\n\n\nA 50:50 mixture of DMEM/F-12 \\(Life Technologies) and Neurobasal medium \\(Life Technologies) containing 1x N2 supplement \\(Life Technologies), 1x B27 supplement \\(Life Technologies), 10 ng/mL bFGF \\(Peprotech), 1% nonessential amino acids \\(Life Technologies), 1mM GlutaMAX \\(Life Technologies), penicillin-streptomycin \\(Life Technologies), 0.1 mM beta-mercaptoethanol \\(Life Technologies), 50 μg/mL BSA \\(Life Technologies), 0.5 μM IM-12 \\(Axon Medchem), 0.5 μM SB590885 \\(Axon Medchem), 1 μM WH-4-023 \\(Axon Medchem), 10 μM Y-27632 \\(Axon Medchem), 20 ng/mL Activin A \\(Peprotech), 20 ng/mL rhLIF \\(Peprotech), 0.5% KSR \\(Life Technologies) and 1 μM PD0325901 \\(Axon Medchem).\r\n\n\n\r\n\n\n_m5i/LAF medium_\r\n\n\nA 50:50 mixture of DMEM/F-12 \\(Life Technologies) and Neurobasal medium \\(Life Technologies) containing 1x N2 supplement \\(Life Technologies), 1x B27 supplement \\(Life Technologies), 10 ng/mL bFGF \\(Peprotech), 1% nonessential amino acids \\(Life Technologies), 1mM GlutaMAX \\(Life Technologies), penicillin-streptomycin \\(Life Technologies), 0.1 mM beta-mercaptoethanol \\(Life Technologies), 50 μg/mL BSA \\(Life Technologies), 0.5 μM IM-12 \\(Axon Medchem), 0.5 μM SB590885 \\(Axon Medchem), 1 μM WH-4-023 \\(Axon Medchem), 10 μM Y-27632 \\(Axon Medchem), 20 ng/mL Activin A \\(Peprotech), 20 ng/mL rhLIF \\(Peprotech), 0.5% KSR \\(Life Technologies) and 0.5 μM PD0325901 \\(Axon Medchem).\r\n\n\n\r\n\n\n_4i/LAF medium with alternative MEK inhibitors_\r\n\n\nA 50:50 mixture of DMEM/F-12 \\(Life Technologies) and Neurobasal medium \\(Life Technologies) containing 1x N2 supplement \\(Life Technologies), 1x B27 supplement \\(Life Technologies), 10 ng/mL bFGF \\(Peprotech), 1% nonessential amino acids \\(Life Technologies), 1mM GlutaMAX \\(Life Technologies), penicillin-streptomycin \\(Life Technologies), 0.1 mM beta-mercaptoethanol \\(Life Technologies), 50 μg/mL BSA \\(Life Technologies), 0.5 μM IM-12 \\(Axon Medchem), 0.5 μM SB590885 \\(Axon Medchem), 1 μM WH-4-023 \\(Axon Medchem), 10 μM Y-27632 \\(Axon Medchem), 20 ng/mL Activin A \\(Peprotech), 20 ng/mL rhLIF \\(Peprotech), 0.5% KSR \\(Life Technologies).\r\n\n\nThe medium can then be supplemented with one of the following inhibitors at 0.5 μM: Refametinib \\(Selleck Chemicals), TAK-733 \\(Selleck Chemicals), Cobimetinib \\(Selleck Chemicals).\r\n\n\n\r\n\n\n_t2iLGöY medium_\r\n\n\nt2iLGöY medium contained a 50:50 mixture of DMEM/F-12 \\(Life Technologies) and Neurobasal medium \\(Life Technologies) containing 1x N2 supplement \\(Life Technologies), 1x B27 supplement \\(Life Technologies), 10 ng/mL bFGF \\(Peprotech), 1% nonessential amino acids \\(Life Technologies), 1 mM GlutaMAX \\(Life Technologies), penicillin-streptomycin \\(Life Technologies), 0.1 mM beta-mercaptoethanol \\(Life Technologies), 50 μg/mL BSA \\(Life Technologies), 1 μM PD0325901 \\(Axon Medchem), 1 μM CHIR99021 \\(Axon Medchem), 2.5 μM Gö6983 \\(Axon Medchem), 10 μM Y-27632 \\(Axon Medchem), 20 ng/mL hLIF \\(Peprotech) and 50 μg/ml ascorbic acid \\(Sigma-Aldrich).\r\n\n\n\r\n\n\nAll culture media were filtered before use with a 0.22μm filter \\(Corning).\r\n\n\n\r\n\n\n_Culturing human embryonic stem cells in conventional primed condition_",
    {
        "title": "1.",
        "body": "Conventional primed human ESCs \\(WIBR3 cell line, DPE-OCT4GFP<sup>5</sup>, UCLA1, UCLA3, UCLA4, UCLA5, UCLA9 and UCLA17 cell lines) are maintained in a feeder-free TeSR-E8 medium and passaged every 4-5 days at 1:4 ratio."
    },
    {
        "title": "2.",
        "body": "Before passaging, coat culture wells with Matrigel \\(Corning) for 30 minutes at 37C."
    },
    {
        "title": "3.",
        "body": "For passaging, wash primed hESCs with PBS \\(Life Technologies) and then add Versene solution \\(Life Technologies) for ~5 minutes. Aspirate the Versene solution, wash with PBS \\(Life Technologies), add fresh TeSR-E8 \\(Stem Cell Technologies) and break the colonies into small clumps by gently pipetting. 10 μM Y- 27632 \\(Axon Medchem) can be added to the TeSR-E8 media to improve hESC survival rate."
    },
    {
        "title": "4.",
        "body": "Cells are cultured in a 37C, 5% O2 and 5% CO2 incubator and media are changed every day. NOTE: Primed hESCs are frozen in mFreSR medium \\(Stem Cell Technologies) following the manufacturer instructions.\r\n  \r\n\n\n_Conversion of primed hESCs to a naive state_\r\n\n\n\r\n\n\n_5i/LAF culture condition:_"
    },
    {
        "title": "1.",
        "body": "For conversion of primed hESCs to a naïve state, irradiated CF-1 MEFs \\(2.5x10<sup>6</sup> cells per 9.5 cm2) are plated the day before in MEF medium on Matrigel coated dishes."
    },
    {
        "title": "2.",
        "body": "Primed hESCs are treated with TrypLE expressed enzyme for 3-5 minutes, dissociated into a single-cell suspension and plated at a density of 30.000 cells per 9.5cm2 on irradiated CF-1 MEFs in TeSR-E8 medium supplemented with 10 μM Y-27632 \\(Axon Medchem)."
    },
    {
        "title": "3.",
        "body": "The medium is replaced the day after with fresh TeSR-E8."
    },
    {
        "title": "4.",
        "body": "Two days after passaging, medium is changed to 5i/LAF and then replaced daily."
    },
    {
        "title": "5.",
        "body": "After 8-10 days naive-like hESCs are passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:1-1:2 ratio. Dome-shaped colonies usually arise after 2-3 passages."
    },
    {
        "title": "6.",
        "body": "Naive hESCs are passaged every 6-7 days. For passaging, naive hESCs are treated with Accutase \\(Life technologies) for five minutes at 37C, dissociated into a single-cell suspension and resuspended in MEF medium. Cells are then filtered through a cell strainer \\(40 μM, Corning), centrifuged at 300g for 5 minutes and seeded on fresh irradiated MEFs in 5i/LAF medium.\r\n  \r\n\n\n_m5i/LAF culture condition:_"
    },
    {
        "title": "1.",
        "body": "For conversion of primed hESCs to a naïve state, irradiated CF-1 MEFs \\(2.5x10<sup>6</sup> cells per 9.5 cm2) are plated the day before in MEF medium on Matrigel coated dishes."
    },
    {
        "title": "2.",
        "body": "Primed hESCs are treated with TrypLE expressed enzyme, dissociated into a single-cell suspension and plated at a density of 30.000 cells per 9.5cm2 on irradiated CF-1 MEFs in TeSR-E8 medium supplemented with 10 μM Y-27632 \\(Axon Medchem)."
    },
    {
        "title": "3.",
        "body": "The medium is replaced the day after with fresh TeSR-E8."
    },
    {
        "title": "4.",
        "body": "Two days after passaging, medium is changed to m5i/LAF and then replaced daily."
    },
    {
        "title": "5.",
        "body": "After 8-10 days naive-like hESCs are passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:1-1:2 ratio. Dome-shaped colonies usually arise after 3-5 passages.\r\n  NOTE: for some primed hESCs \\(i.e. UCLA1, UCLA9, UCLA17), the naïve conversion can be very inefficient in m5i/LAF medium. For this reason, it may be necessary to pick individual colonies to expand a homogenous population of naïve cells. We also note that the use of bFGF for expansion in m5i/LAF condition is not recommended."
    },
    {
        "title": "6.",
        "body": "Naive hESCs are passaged every 6-7 days. For passaging, hESCs are treated with Accutase \\(Life technologies) for five minutes at 37C, dissociated into a single-cell suspension and resuspended in MEF medium. Cells are then filtered through a cell strainer \\(40 μM, Corning), centrifuged at 300g for 5 minutes and seeded on fresh irradiated MEFs in m5i/LAF medium.\r\n  NOTE: The PD03 concentration for the m5i/LAF medium may vary depending on the starting cell line. Thus, we recommend doing a titration of PD03 for each individual hESC line.\r\n\n\n\r\n\n\n_4i/LAF with Alternative MEKi:_"
    },
    {
        "title": "1.",
        "body": "For conversion of primed hESCs to a naïve state, irradiated CF-1 MEFs \\(2.5x106 cells per 9.5 cm2) are plated the day before in MEF medium on Matrigel coated dishes."
    },
    {
        "title": "2.",
        "body": "hESCs are treated with TrypLE expressed enzyme, dissociated into a single-cell suspension and plated at a density of 30.000 cells per 9.5cm2 on irradiated CF-1 MEFs in TeSR-E8 medium supplemented with 10 μM Y-27632 \\(Axon Medchem)."
    },
    {
        "title": "3.",
        "body": "The medium is replaced the day after with fresh TeSR-E8."
    },
    {
        "title": "4.",
        "body": "Two days after passaging, medium is changed to 4i/LAF supplemented with 0.5 μM of one of the alternative MEK inhibitors and then replaced daily."
    },
    {
        "title": "5.",
        "body": "Cells are passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:1-1:2 ratio. Dome-shaped colonies usually arise after 3-5 passages."
    },
    {
        "title": "6.",
        "body": "Naive hESCs are passaged every 6-7 days. For passaging, hESCs are treated with Accutase \\(Stem cell technologies) for five minutes at 37C, dissociated into a single-cell suspension and resuspended in MEF medium. Cells are then filtered through a cell strainer \\(40 μM, Corning), centrifuged at 300g for 5 minutes and seeded on fresh irradiated MEFs in 4i/LAF medium supplemented with 0.5 μM of one of the alternative MEK inhibitors.\r\n  \r\n\n\n_5i/LAF to m5i/LAF transition:_"
    },
    {
        "title": "1.",
        "body": "Some primed hESC lines can be resistant to naïve conversion in m5i/LAF conditions \\(i.e. UCLA3).  In these cases, cells are converted in 5i/LAF medium and then switched to m5i/LAF medium after 5-6 passages in culture."
    },
    {
        "title": "2.",
        "body": "Cells at P5 in 5i/LAF medium are passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:3."
    },
    {
        "title": "3.",
        "body": "The day after the cells are switched to m5i/LAF medium and passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:2-1:3 ratio every 6-7 days."
    },
    {
        "title": "4.",
        "body": "For passaging, hESCs are treated with Accutase \\(Life technologies) for five minutes at 37C, dissociated into a single-cell suspension and resuspended in MEF medium. Cells are then filtered through a cell strainer \\(40 μM, Corning), centrifuged at 300g for 5 minutes and seeded on fresh irradiated MEFs in m5i/LAF medium.\r\n  \r\n\n\n_5i/LAF to t2iLGöY transition:_"
    },
    {
        "title": "1.",
        "body": "For conversion of 5i/LAF adapted naïve cells in t2iLGöY conditions, naive hESCs grown in 5i/LAF medium at P>8 are passaged onto a fresh layer of irradiated CF-1 MEFs."
    },
    {
        "title": "2.",
        "body": "The day after the cells are switched to t2iLGöY medium and passaged onto a fresh layer of irradiated CF-1 MEFs at a 1:3 ratio every 6-7 days."
    },
    {
        "title": "3.",
        "body": "For passaging, hESCs are treated with Accutase \\(Life technologies) for five minutes at 37C, dissociated into a single-cell suspension and resuspended in MEF medium. Cells are then filtered through a cell strainer \\(40 mM, Corning), centrifuged at 300g for 5 minutes and seeded on fresh irradiated MEF in t2iLGöY medium."
    },
    {
        "title": "4.",
        "body": "NOTE: we have expanded the hESC in t2iLGöY for at least 4 passages. In addition, some hESC lines \\(i.e. UCLA17, UCLA3) cannot be adapted to the t2iLGöY while maintaining naïve pluripotency."
    }
]